US Stock MarketDetailed Quotes

ELDN Eledon Pharmaceuticals

Watchlist
  • 3.240
  • -0.120-3.57%
Close Apr 25 16:00 ET
  • 3.040
  • -0.200-6.17%
Pre 08:43 ET
194.02MMarket Cap-4.32P/E (TTM)

About Eledon Pharmaceuticals Company

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.

Company Profile

SymbolELDN
Company NameEledon Pharmaceuticals
Listing DateSep 17, 2014
Issue Price15.00
Founded2004
CEODr. David-Alexandre C. Gros, M.D.
MarketNASDAQ
Employees31
Fiscal Year Ends12-31
Address19800 MacArthur Boulevard,Suite 250
CityIrvine
ProvinceCalifornia
CountryUnited States of America
Zip Code92612
Phone1-949-238-8090

Company Executives

  • Name
  • Position
  • Salary
  • Dr. David-Alexandre C. Gros, M.D.
  • Director and Chief Executive Officer
  • 2.55M
  • Paul Sean Little
  • Chief Financial Officer and Principal Accounting Officer
  • 1.32M
  • Bryan E. Smith
  • General Counsel, Corporate Secretary and Chief Compliance Officer
  • --
  • Dr. Steven N. Perrin, PhD
  • President, Chief Scientific Officer, Director
  • 1.54M
  • Keith A. Katkin
  • Chairman of the Board
  • 1.52M
  • Walter C. Ogier
  • Independent Director
  • 371.82K
  • John S. McBride
  • Independent Director
  • 371.82K
  • James Robinson
  • Independent Director
  • 201.79K
  • Dr. June Lee, M.D.
  • Independent Director
  • 374.44K
  • Dr. Jan L. Hillson, M.D.
  • Independent Director
  • 353.44K
  • Dr. Allan Douglas Kirk, F.A.C.S.,M.D.,PhD
  • Independent Director
  • 198.80K

Market Insights

Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

Unlock Now

Discussing

2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current Show More
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Unlock Now
U.S Tech Companies U.S Tech Companies

U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.

Unlock Now
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks

Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.

Unlock Now

Reassessing Chinese Assets

Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.